Engineering a Miniprotein for Tumor Imaging
Author Information
Author(s): Kimura Richard H., Jones Douglas S., Jiang Lei, Miao Zheng, Cheng Zhen, Cochran Jennifer R.
Primary Institution: Stanford University
Hypothesis
Can the Ecballium elaterium trypsin inhibitor (EETI-II) be engineered to enhance binding to tumor-associated integrin receptors?
Conclusion
The study successfully engineered a knottin peptide that binds with high affinity to tumor-associated integrin receptors, showing potential for non-invasive imaging.
Supporting Evidence
- The engineered knottin peptide showed high affinity binding to αvβ3 and αvβ5 integrins.
- IC50 values for the knottin peptides were determined in the low nanomolar range.
- A radiolabeled version demonstrated favorable tumor-to-muscle and tumor-to-blood ratios.
- Binding assays confirmed the specificity of the engineered peptides for integrin receptors.
Takeaway
Scientists made a tiny protein that can stick to cancer cells, helping doctors see tumors better using special imaging.
Methodology
Yeast surface display was used to engineer an EETI-II mutant with two integrin binding loops, followed by binding affinity and specificity assays.
Limitations
Reduced serum and metabolic stability were observed compared to previous EETI-II variants.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website